Opinion

Video

Resource Allocation in the Treatment of Dry Eye Disease

A panel of medical experts discuss the shift from intervention to prevention in the management of dry eye disease, as well as perspectives on resource allocation.

This is a video synopsis/summary of a Stakeholder Summit involving:

Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.

Haumschild asks about aligning dry eye disease (DED) management with overall health care spending trends. Parekh notes the shift from intervention to prevention. Earlier DED detection enables disease-modifying therapy like artificial tears and behavioral changes for sustained benefits vs allowing progression and irreversible damage. This prevents exponentially higher costs with severe late-stage DED. Upfront DED investment reflects a value shift toward comprehensive eye care beyond surgery and glasses. The average DED patient age has dropped into the 30s, driven by digital device use, representing expanded need. Central corneal staining in young patients highlights the growth of DED. Broad DED coverage and early access are thus increasingly warranted from clinical, social, and economic standpoints.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo